A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Thousand Oaks-based Capsida Biotherapeutics will be receiving $40 million from biotech giant AbbVie after the South San Francisco-based company exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Announced Jan. 7, Capsida will receive $40 million under a license…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
